Rock Springs Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Rock Springs Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$208K	Sell	10,696 -51,004	-83%	-$925K	0.01%	104
2026 Q1	$1.15M	Hold	61,700	–	–	0.07%	93
2025 Q4	$813K	Buy	61,700 +33,500	+119%	+$395K	0.04%	96
2025 Q3	$202K	Buy	+28,200	New	+$1.47M	0.01%	91
2021 Q4	–	Sell	-154,500	Closed	-$1.54M	–	144
2021 Q3	$1.54M	Hold	154,500	–	–	0.03%	146
2021 Q2	$1.6M	Hold	154,500	–	–	0.03%	149
2021 Q1	$1.58M	Hold	154,500	–	–	0.03%	145
2020 Q4	$1.76M	Buy	+154,500	New	+$1.64M	0.04%	149

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rock Springs Capital Management's MLTX Position: Q2 2026 in Review

Rock Springs Capital Management reduced its MoonLake Immunotherapeutics (MLTX) stake by 83% in Q2 2026, selling an estimated $925K and leaving 10,696 shares worth $208K. The position accounts for 0.01% of the portfolio, ranked #104.

Rock Springs Capital Management first reported a position in MLTX in Q4 2020 and has held it in 8 quarters since. The position peaked at $1.76M in Q4 2020. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Rock Springs Capital Management held 10,696 shares of MoonLake Immunotherapeutics worth $208K as of Q2 2026.
Rock Springs Capital Management sold 51,004 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $925K.
MoonLake Immunotherapeutics made up 0.01% of Rock Springs Capital Management's portfolio in Q2 2026, its #104 holding.
Rock Springs Capital Management first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 8 quarters since.
Rock Springs Capital Management's MoonLake Immunotherapeutics position peaked at $1.76M in Q4 2020.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.